Phase III Trial Tests SALI-10 Probiotic Against Radiation Dental Toxicity
Start here
A Phase III randomized controlled trial, registered as NCT07883005 and titled SALI-10, will test whether a probiotic lozenge can reduce major adverse dental events in patients receiving radiation therapy for head and neck cancer. The trial plans to enroll 288 patients, each randomly assigned to either standard of care or standard of care plus SALI-10 lozenges. Its primary endpoint is tooth failure and/or grade 2 or higher jaw osteoradionecrosis. The study is not yet recruiting, with a planned start date of 2026-11-01. Patient accrual and results remain ahead: whether SALI-10 can meaningfully lower the risk of these radiation-related dental and jaw complications will only become clear once the trial is underway and completes follow-up.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- clinicaltrials.govPickSALI-10 Probiotic to Reduce Osteoradionecrosis and Dental Toxicity Following Radiation Therapy for Head and Neck Cancer
NCT07883005 plans to enroll 288 patients with head and neck cancer in a Phase III randomized controlled trial evaluating whether SALI-10 can reduce the risk of radiation-related major adverse dental events (MADE). Patients will be randomly assigned to standard of care or standard of care plus SALI-10 lozenges; MADE is defined as tooth failure and/or grade 2 or higher jaw osteoradionecrosis. The trial is not yet recruiting and is planned to start on 2026-11-01.
Heat trend for this story
Not enough continuous observation yet to draw a trend.